BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
BioMarin entered an exclusive license for a Fabry disease therapy from GC Biopharma and Hanmi Pharm.
Related stories
Origin Energy Q1 APLNG Revenue Jumps on Higher Prices and Data Centre Demand
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Seatrium Secures FPSO Integration Contract Worth Over S$200 Million
Seatrium secured an FPSO integration contract valued at over S$200 million from SBM Offshore.
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Global market picture: S&P 500 -0.62%, Nasdaq 100 -1.54%; EUR/USD +0.26%, WTI +0.83%
Global market picture. US index futures: S and P futures is down 0.62 percent, Nasdaq futures is down 1.54 percent, Dow futures is up 0.06 percent and Russell futures is down 0.03
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Teck Resources Publishes Q3 2026 Earnings Call Transcript
M impact | EQUITY | Oct 29, 2026, 11:59 PM UTC
Aecon Group Reports Quarterly Results Through September 30
Aecon Group reported results for the quarter ended September 30. Figures are in Canadian dollars unless otherwise stated.
M impact | EQUITY | Oct 29, 2026, 11:58 PM UTC
Eastman Chemical Reports Quarterly Results Through September 30
The LSEG-generated earnings summary covers Eastman Chemical Co.'s quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:58 PM UTC